Patenting Bioprinting Technologies in the US and Europe – The Fifth Element in the Third Dimension

By Timo Minssen

I am happy to announce the publication of our new working paper on  “Patenting Bioprinting Technologies in the US and Europe – The 5th element in the 3rd dimension.” The paper, which has  been co-authored by Marc Mimler, starts out by describing the state of the art and by examining what sorts of bioprinting inventions are currently being patented. Based on our findings we then discuss what types of future innovations we can expect from the technological development and how far these would and/or should be protectable under European and US patent laws.

The paper is forthcoming in: RM Ballardini, M Norrgård & J Partanen (red), 3D printing, Intellectual Property and Innovation – Insights from Law and Technology. Wolters Kluwer, but the working paper is already available on SSRN.

Abstract

The enormous opportunities and the broader implications of bioprinting raise a wide variety of crucial legal issues. These may range from the regulation of the science and its’ societal effects to questions regarding the commercialization of the technology. Regarding commercialization aspects, one issue that must be addressed concerns the question of what types of products and uses should be regarded as protectable subject matter under the relevant intellectual property right (IPR) frameworks. Considering that the availability IPRs might have a great impact on where the greatest investments and scientific efforts in this technology will made, this is an utterly important question. In addition to trade secrets, copyrights, trademarks and other IPR-related rights, patents will certainly play a major role in that respect and will be at the focus of this paper.

In this paper, we examine what sorts of bioprinting- inventions are being patented or would be- protectable under European and US patent laws. Rather than focusing on the highly relevant questions that 3D printing poses for patent infringement doctrines and research exemptions, this paper concentrates on the question of patentable subject matter and patentability. To this end, we start out by (1) briefly describing the relevant state of the art in bioprinting. This allows us to better describe and understand the current bioprinting patent landscape (2), and to examine in how far any future inventions stemming from such technology would meet the most basic U.S. and European patent requirements (3). A related question is of course, if some bioprinting technologies should be categorically excluded from patentability, i.e. even when meeting the most basic patent criteria. We address this specific issue by discussing patent- limitations and morality exclusions from patent law (4), which will allow us to complete the paper with some concluding remarks (5).

Suggested Citation

Minssen, T & Mimler, M 2017, “Patenting Bioprinting Technologies in the US and Europe– The 5th element in the 3rd dimension”, Working Paper, forthcoming in: RM Ballardini, M Norrgård & J Partanen (red), 3D printing, Intellectual Property and Innovation – Insights from Law and Technology. Wolters Kluwer. Available at SSRN: https://papers.ssrn.com/sol3/papers.cfm?… .

 

This entry was posted in Bioethics, Biotechnology, Cloning, Enhancement, FDA, Genetics, Health Law Policy, Human Rights, Human Tissue, Intellectual Property, Neuroscience, Organs, Pharmaceuticals, Research Funding, Stem Cells, Timo Minssen and tagged , , , , , , , , by Timo Minssen. Bookmark the permalink.

About Timo Minssen

Timo Minssen is Professor of Law specializing in legal aspects of biomedical innovation at the University of Copenhagen (UCPH). He is the Managing Director and Founder of UCPH's new Center for Advanced Studies and Collaborative Research Programme in Biomedical Innovation Law (CeBIL). Previously, Timo had been Professor of Biotechnology Law at UCPH's Centre for Information & Innovation Law (CIIR), Visiting Research Fellow at the Universities of Cambridge and Oxford (UK), Harvard Law School and at the Chicago-Kent College of Law (US), as well as Max Planck stipendiate at the Max Planck Institute for Innovation & Competition in Munich (Germany). Moreover, he was trained in the German Court system (Referendariat) and worked for shorter periods at the European Patent Office (EPO), leading law firms, tech start-ups and and for an interdisciplinary epigenetics project as a fellow of the Swedish Pufendorf Institute for Advanced Studies.. Timo holds a German law degree (Staatsexamen) from Georg-August-University in Göttingen, as well as Swedish biotech & IPR related LL.M., LL.Lic., and LL.D. degrees from Lund University and Uppsala University. His PhD thesis delivered a comprehensive study on the patentability of biopharmaceutical technology in the US & Europe, which received the Swedish King Oscar award. He has also received the Awapatent and Jorcks Foundation Research Prizes and was a finalist of the Swedish Wallenberg Academy Fellows program.